Roche's bitopertin failed to improve the negative symptoms of schizophrenia in two pivotal trials, raising questions about the therapeutic potential of glycinergic neuromodulation.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The impact of D-cycloserine and sarcosine on in vivo frontal neural activity in a schizophrenia-like model
BMC Psychiatry Open Access 25 October 2019
-
1-Aminocyclopropanecarboxylic acid (ACPC) produces procognitive but not antipsychotic-like effects in rats
Psychopharmacology Open Access 27 September 2014
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
PowerPoint slides
Rights and permissions
About this article
Cite this article
Kingwell, K. Schizophrenia drug gets negative results for negative symptoms. Nat Rev Drug Discov 13, 244–245 (2014). https://doi.org/10.1038/nrd4294
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4294